Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hoffmann-La Roche Ltd: U.S. FDA grants priority review to Roche's Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults

Investegate announcements from F. Hoffmann-La Roche Ltd, U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults

Related Keywords

Japan ,Honduras ,Australia ,Philippines ,United States ,Horby ,Vinnyts Ka Oblast ,Ukraine ,Hong Kong ,United Kingdom ,Bolivia ,Guatemala ,Canada ,New Zealand ,Ghana ,Ecuador ,Chile ,Peru ,Switzerland ,America ,Nathalie Meetz ,Levi Garraway ,Actemra Roactemra ,Loren Kalm ,Roche Actemra Roactemra ,Genentech ,Gilead Sciences Inc ,European Union ,Tools Accelerator Initiative ,United States Department Of Health ,Biomedical Advanced Research ,Human Services ,Drug Administration ,World Health Organization ,Head Of Global Product Development ,Development Authority ,Clinical Trial Programme ,Office Of The ,Roche Group ,Roche Group Media Relations ,Biologics License Application ,Priority Review ,Chief Medical Officer ,Global Product Development ,Emergency Use Authorization ,World Health ,Assistant Secretary ,United States Department ,New England Journal ,Gilead Sciences ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Between March ,Hospitalized Patients ,Patients Hospitalized ,Investegate Announcements ,Investegate Company Announcements ,F Hoffmann La Roche Ltd ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,